FINGOLIMOD HYDROCHLORIDE: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Accord Hlthcare	FINGOLIMOD HYDROCHLORIDE	fingolimod hydrochloride	CAPSULE;ORAL	207991	ANDA	Accord Healthcare Inc.	16729-342-10	30 CAPSULE in 1 BOTTLE (16729-342-10)	2022-10-18
Alkem Labs Ltd	FINGOLIMOD HYDROCHLORIDE	fingolimod hydrochloride	CAPSULE;ORAL	208004	ANDA	Ascend Laboratories, LLC	67877-476-30	30 CAPSULE in 1 BOTTLE (67877-476-30)	2022-09-21
Alkem Labs Ltd	FINGOLIMOD HYDROCHLORIDE	fingolimod hydrochloride	CAPSULE;ORAL	208004	ANDA	Ascend Laboratories, LLC	67877-476-32	7 BLISTER PACK in 1 CARTON (67877-476-32) / 7 CAPSULE in 1 BLISTER PACK	2022-09-21
Alkem Labs Ltd	FINGOLIMOD HYDROCHLORIDE	fingolimod hydrochloride	CAPSULE;ORAL	208004	ANDA	Ascend Laboratories, LLC	67877-476-33	10 BLISTER PACK in 1 CARTON (67877-476-33) / 10 CAPSULE in 1 BLISTER PACK	2022-09-21
Alkem Labs Ltd	FINGOLIMOD HYDROCHLORIDE	fingolimod hydrochloride	CAPSULE;ORAL	208004	ANDA	Ascend Laboratories, LLC	67877-476-56	28 CAPSULE in 1 BOTTLE (67877-476-56)	2022-09-21
Alkem Labs Ltd	FINGOLIMOD HYDROCHLORIDE	fingolimod hydrochloride	CAPSULE;ORAL	208004	ANDA	Ascend Laboratories, LLC	67877-476-58	28 BLISTER PACK in 1 CARTON (67877-476-58) / 14 CAPSULE in 1 BLISTER PACK (67877-476-14)	2022-09-21
Apotex	FINGOLIMOD HYDROCHLORIDE	fingolimod hydrochloride	CAPSULE;ORAL	207993	ANDA	Apotex Corp.	60505-4332-3	30 CAPSULE in 1 BOTTLE (60505-4332-3)	2022-10-18
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This analysis identifies and profiles key global suppliers of fingolimod hydrochloride, examining their manufacturing capabilities and the patent landscape surrounding the active pharmaceutical ingredient (API). Understanding these elements is critical for pharmaceutical companies involved in the development, manufacturing, and commercialization of fingolimod-based therapeutics.

What is Fingolimod Hydrochloride?

Fingolimod hydrochloride is an immunomodulating drug approved for the treatment of relapsing forms of multiple sclerosis (MS) in adults. It is a sphingosine-1-phosphate (S1P) receptor modulator. By binding to S1P receptors on lymphocytes, it prevents them from migrating from lymph nodes to the central nervous system, thereby reducing inflammation and the autoimmune attack on myelin. The drug is marketed by Novartis as Gilenya.

Manufacturing and Supply Chain for Fingolimod Hydrochloride API

The production of fingolimod hydrochloride API requires specialized chemical synthesis and adherence to stringent Good Manufacturing Practice (GMP) standards. Multiple companies globally have developed the capacity to produce this complex molecule.

Primary API Manufacturers

The following companies are identified as significant manufacturers of fingolimod hydrochloride API, based on regulatory filings, industry reports, and market presence.

Novartis AG: As the originator of fingolimod (Gilenya), Novartis maintains significant internal manufacturing capabilities. Its primary manufacturing sites are subject to strict regulatory oversight.
Hetero Drugs Limited: An Indian pharmaceutical company, Hetero has established itself as a major supplier of generic APIs. Its regulatory filings indicate production of fingolimod hydrochloride, supporting its entry into various global markets.
Dr. Reddy's Laboratories: Another prominent Indian pharmaceutical firm, Dr. Reddy's has a strong API division and is known to produce a range of complex molecules, including fingolimod hydrochloride.
Sun Pharmaceutical Industries Ltd.: Sun Pharma is one of the largest generic pharmaceutical companies globally and has a substantial API manufacturing infrastructure. Its portfolio includes various immunosuppressants and neurological drugs.
Cipla Limited: Cipla is an Indian multinational pharmaceutical company that manufactures and supplies a broad spectrum of APIs. It has demonstrated capabilities in producing complex APIs for various therapeutic areas.
Teva Pharmaceutical Industries Ltd.: A global leader in generic pharmaceuticals, Teva has extensive API manufacturing facilities and regulatory expertise, making it a potential supplier for fingolimod hydrochloride.
Sandoz (a Novartis division): While part of Novartis, Sandoz operates as a separate entity focused on generics and biosimilars. It is positioned to manufacture and supply fingolimod hydrochloride as a generic product.
Venkateshwara Hatcheries Limited (VHL) / Biological E. Limited: VHL, through its subsidiary Biological E. Limited, is a significant player in the Indian pharmaceutical API market and has the capability for complex organic synthesis.

Key Considerations for API Sourcing

When evaluating API suppliers, several factors are paramount:

GMP Compliance: All manufacturing sites must meet current Good Manufacturing Practices (cGMP) as defined by regulatory bodies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and others. This includes robust quality control systems, process validation, and impurity profiling.
Regulatory Filings: The supplier's ability to file Drug Master Files (DMFs) or equivalent documentation in key target markets (e.g., US FDA DMF, CEP for Europe) is essential for the drug product manufacturer.
Capacity and Scalability: The supplier must demonstrate sufficient manufacturing capacity to meet projected demand and the ability to scale production if necessary.
Supply Chain Reliability: Redundancy in manufacturing sites and robust supply chain management are critical to mitigate risks of disruption.
Cost and Pricing Stability: Competitive pricing and predictable cost structures are vital for commercial viability.
Intellectual Property (IP) Clearance: Suppliers must operate in a manner that respects existing patents and regulatory exclusivities.

Patent Landscape for Fingolimod Hydrochloride

The patent landscape for fingolimod hydrochloride, particularly concerning its synthesis and formulations, significantly influences market entry for generic products and potential new therapeutic applications.

Key Patents and Expiries

The original patent protection for fingolimod as a new chemical entity has largely expired in major markets. However, secondary patents related to specific formulations, manufacturing processes, and methods of use can still present barriers or opportunities.

Composition of Matter Patents: The foundational patent covering fingolimod itself (and its salts/hydrates) has expired. For instance, U.S. Patent 5,604,229, originally filed by Merck KGaA and later licensed to Novartis, covered fingolimod. This patent expired well before the current commercial period.
Formulation Patents: Patents covering specific crystalline forms (polymorphs), salt forms, or pharmaceutical compositions that enhance stability, bioavailability, or patient compliance can extend market exclusivity. Examples include patents on specific hydrochloride salt forms or controlled-release formulations.
Process Patents: Patents claiming novel or improved methods of synthesizing fingolimod hydrochloride are crucial. These can offer a competitive advantage by reducing costs, improving purity, or increasing yield. Manufacturers seeking to enter the market must carefully navigate these to avoid infringement.
Method of Use Patents: Patents covering specific therapeutic uses of fingolimod hydrochloride, such as for certain types of MS or other indications, can extend the effective exclusivity period.

Patent Expiry Trends

The expiration of primary patents has paved the way for generic competition. However, the landscape is dynamic, with ongoing patent filings and litigation around secondary patents.

U.S. Market: The primary patents for Gilenya in the U.S. expired, leading to the introduction of generic versions. Litigation has occurred around secondary patents, with various outcomes affecting market entry timelines for generics. For example, the expiration of the Compound Patent and Formulation Patent [1] are key dates.
European Market: Similar to the U.S., key patents have expired. Supplementary Protection Certificates (SPCs) in Europe can extend patent term based on the duration of the basic patent and marketing authorization.
Other Markets: Patent expiry timelines vary by country, influenced by local patent laws and data exclusivity periods.

Impact of Patents on Generic Entry

Freedom to Operate (FTO): Generic manufacturers must conduct thorough FTO analyses to ensure their manufacturing processes and proposed formulations do not infringe on existing, valid patents.
Patent Litigation: Disputes over patent validity and infringement are common. Successful challenges to secondary patents can accelerate generic market entry, while successful defense by the innovator can delay it.
ANDA Filings (U.S.): The Abbreviated New Drug Application (ANDA) process in the U.S. requires applicants to certify that their product does not infringe on listed patents or that such patents are invalid, unenforceable, or will expire before the generic product's market entry.
Hatch-Waxman Act: This U.S. legislation provides incentives for both brand and generic drug development, including periods of market exclusivity and a pathway for generic drug approval.

Key Patent Landscape Players

Novartis AG: Holds the original patents and has actively sought to protect its market position through secondary patents and patent term extensions.
Generic Manufacturers: Companies like Hetero, Dr. Reddy's, Sun Pharma, and Teva are actively engaged in navigating the patent landscape to secure market entry for their generic fingolimod hydrochloride products. Their R&D efforts are often focused on developing non-infringing synthesis routes and formulations.
Patent Litigation Firms: Specialized legal firms play a crucial role in patent prosecution, defense, and litigation for both innovator and generic companies.

Regulatory Approvals and Market Dynamics

The approval status of fingolimod hydrochloride by major regulatory bodies underpins its commercial availability.

U.S. FDA: Gilenya was approved by the FDA in September 2010. Generic fingolimod hydrochloride products have subsequently received FDA approval.
European Medicines Agency (EMA): The EMA granted marketing authorization for Gilenya in September 2011. Generic versions have also been approved.
Other Regulatory Bodies: Approvals exist in numerous other countries, including Japan, Canada, and Australia.

The market for fingolimod hydrochloride is characterized by the presence of both the innovator product and increasing competition from generic manufacturers. This competition typically leads to price reductions and expanded patient access.

Key Takeaways

Diversified API Supply: A global network of API manufacturers, primarily in India and Europe, is capable of producing fingolimod hydrochloride under GMP conditions.
Novartis's Dominance: As the originator, Novartis retains significant internal manufacturing and has been a key player in establishing the initial supply chain.
Generic Market Expansion: The expiration of core patents has enabled generic manufacturers to enter the market, increasing competition and driving down prices.
Dynamic Patent Landscape: While composition of matter patents have expired, secondary patents related to formulations and manufacturing processes continue to shape market entry strategies and can be subject to litigation.
Regulatory Scrutiny: All API suppliers and finished dosage form manufacturers must adhere to strict GMP standards and navigate complex regulatory approval processes in each target market.

Frequently Asked Questions

What is the primary therapeutic indication for fingolimod hydrochloride?

Fingolimod hydrochloride is primarily indicated for the treatment of relapsing forms of multiple sclerosis in adults.

Which countries have the largest API manufacturing capacity for fingolimod hydrochloride?

India and European countries host a significant portion of the global API manufacturing capacity for fingolimod hydrochloride.

Are there any active patents that prevent the manufacturing of generic fingolimod hydrochloride?

While primary patents have expired, secondary patents related to specific manufacturing processes or unique formulations may still be active and require careful assessment for freedom to operate.

What are the quality control requirements for fingolimod hydrochloride API suppliers?

Suppliers must comply with current Good Manufacturing Practices (cGMP), which include stringent quality control of raw materials, in-process testing, final product release testing, and robust impurity profiling.

How does the patent expiry impact the price of fingolimod hydrochloride?

Patent expiry typically leads to increased competition from generic manufacturers, which generally results in a significant decrease in the price of fingolimod hydrochloride.

What is the role of Drug Master Files (DMFs) in the fingolimod hydrochloride supply chain?

Drug Master Files (DMFs) provide confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of a drug. They are submitted to regulatory agencies (like the FDA) to support drug product applications and allow API manufacturers to safeguard proprietary information while assuring regulatory compliance.

What are the main challenges for new entrants in the fingolimod hydrochloride API market?

Challenges include establishing GMP-compliant manufacturing facilities, securing regulatory approvals (e.g., FDA DMF, CEP), demonstrating cost-effective and non-infringing synthesis routes, and managing supply chain reliability against established players.

What is the typical shelf life of fingolimod hydrochloride API?

The typical shelf life for an API like fingolimod hydrochloride is generally determined by stability studies and can range from two to five years when stored under recommended conditions, but specific manufacturer data is required.

How is the impurity profile of fingolimod hydrochloride managed?

Impurity profiling is a critical aspect of API manufacturing. Manufacturers identify, quantify, and control known and potential impurities through process optimization, validated analytical methods, and adherence to ICH guidelines to ensure patient safety.

What are the regulatory implications of using a fingolimod hydrochloride API from a new supplier?

Using a new supplier requires rigorous due diligence, including auditing the manufacturing site, reviewing quality agreements, verifying regulatory filings (DMFs), and ensuring the new API meets all pharmacopoeial standards and product-specific requirements.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.accessdata.fda.gov/scripts/cder/ob/

Suppliers and packagers for generic pharmaceutical drug: FINGOLIMOD HYDROCHLORIDE